Articles tagged "Induction therapy"

2020 American Transplant Congress
Single-Dose Anti-Thymocyte Globulin is Non-Inferior to Divided-Dose for Induction Therapy in Kidney and Pancreas Transplantation
A. I. Ingemi¹, O. F. Bangash¹, S. McCoy¹, L. Hulse², J. Colonna¹, H. Sadr¹, S. Sutton¹, M. Coleman¹, T. Wilson¹, T. R. McCune¹
¹Sentara Norfolk General Hospital, Norfolk, VA, ²Children's Hospital of the King's Daughters, Norfolk, VA
*Purpose: Emerging studies suggest that single-dose rabbit antithymocyte globulin (rATG) is not inferior to the divided-dose, however this dosing strategy has never been evaluated in…
2020 American Transplant Congress
Efficacy and Safety of Single-Dose Rabbit Anti-Thymocyte Globulin versus Basiliximab Induction among Pediatric Kidney Transplant Recipients
L. Porini Custodio, S. Stopa Martins, L. Almeida Viana, M. Pontello Cristelli, M. Rika Nakamura, H. Tedesco-Silva, J. Medina-Pestana
Hospital do Rim, Sao Paulo, Brazil
*Purpose: Induction therapy is a standard component of kidney transplant immunosuppression protocols. However, in the pediatric population, there are still uncertainties about the ideal induction…
2020 American Transplant Congress
Safety and Efficacy of Low Dose Rabbit Antithymocyte Globulin in Pediatric Renal Transplant Recipients
V. K. Sigurjonsdottir¹, L. Maestretti¹, A. McGrath¹, A. Gallo², W. Concepcion², P. Grimm¹, A. Chaudhuri¹
¹Pediatric Nephrology, Stanford University, Stanford, CA, ²Surgery - Multi-Organ Transplantation, Stanford University, Stanford, CA
*Purpose: Currently there is no consensus among pediatric kidney transplant centers regarding the use and regimen for immunosuppressive induction therapy.The safety and effectiveness of reduced…
2020 American Transplant Congress
Incident Malignancies among Post Kidney-Transplant Patients by Type of Induction Immunosuppression and by Age
L. Wang, J. Motter, S. Bae, D. Segev, M. McAdams DeMarco
Johns Hopkins University, Baltimore, MD
*Purpose: Adult kidney-transplant (KT) recipients have a differential risk of malignancies based on their induction immunosuppression (IS) therapy. However, older recipients are more likely to…
2020 American Transplant Congress
Adult Primary Liver Transplant Recipient Outcomes by Immunosuppression Induction Received
T. Shaker¹, G. Larrieux¹, S. Jackson², S. Riad³, T. Pruett¹, T. Leventhal⁴
¹Surgery, Division of Transplantation, University of Minnesota, Minneapolis, MN, ²M Health Fairview, Minneapolis, MN, ³Division of Renal Diseases and Hypertension, University of Minnesota, Minneapolis, MN, ⁴Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN
*Purpose: It has long been recognized that the highest risk of rejection of an organ is in the first few months post transplantation. To prevent…
2020 American Transplant Congress
Basiliximab Induction in the Obese: One Size Does Fit All
A. D. Reticker¹, D. Choi¹, A. B. Lichvar¹, C. Kane², I. Tzvetanov³, E. Benedetti³, J. J. Benken¹
¹Pharmacy Practice, University of Illinois Hospital and Health Sciences System, Chicago, IL, ²Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ³Surgery, University of Illinois Hospital and Health Sciences System, Chicago, IL
*Purpose: Surgical advancements allow more obese (BMI> 30 kg/m2) patients to receive a renal transplant. The original clinical and pharmacokinetic (PK) trials in transplantation immunosuppression…
2020 American Transplant Congress
Evaluation of Infectious and Malignant Complications in Elderly Renal Transplant Recipients Receiving Alemtuzumab Compared to Basiliximab
K. Lang¹, J. Shulte¹, K. Cunningham¹, C. D'Agostino¹, M. Kapugi¹, C. Kane¹, A. Novak¹, J. Leventhal²
¹Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ²Division of Transplant Surgery, Northwestern Memorial Hospital, Chicago, IL
*Purpose: The choice of induction immunosuppression can affect several outcomes after kidney transplant (KTx), especially for elderly recipients. For this population, there is limited data…
2020 American Transplant Congress
Induction Immunosuppression with Thymoglobulin May Improve Graft Outcomes without Increasing a Risk for Infection in Patients Undergoing Liver Transplantation Alone
M. Henry¹, T. Kitajima², J. Konel¹, S. Yeddula², M. Rizzari², K. Collins², D. Moonka², A. Yoshida², M. Abouljoud², S. Nagai³
¹Wayne State University School of Medicine, Detroit, MI, ²Henry Ford Hospital, Detroit, MI, ³Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: Immunosuppression protocols for liver transplant (LT) vary between institutions and roles of induction immunosuppression in LT remain controversial. The aim of this study was…
2020 American Transplant Congress
The Challenge of Selecting an Induction Agent: A Dual Regimen for Medically High-Risk Kidney Recipients
R. Craig-Schapiro, B. Magaoay, R. Grover, S. Sultan, M. Aull, S. Kapur
Weill Cornell Medical Center, New York, NY
*Purpose: Complications of the commonly used lymphocyte-depleting induction agent, rabbit anti-thymocyte globulin (rATG),include cardiorespiratory dysfunction with hypotension, tachycardia, myocardial infarction, and pulmonary edema. The choice…
2019 American Transplant Congress
A Randomized Controlled Clinical Trial of Thymoglobulin® and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver Transplantation: A Multicenter Study
L. Coromina¹, S. Shah², B. Xervos³, M. Zimmerman⁴, K. Sasaki¹, T. Diago¹, K. Hashimoto¹, F. Aucejo¹, m. Fujiki¹, H. Block-Beach¹, A. Patterson², C. Miller¹, C. Quintini¹, B. Eghtesad¹
¹The Cleveland Clinic, Cleveland, OH, ²University of Cincinnati, Cincinnati, OH, ³The Cleveland Clinic, Weston, FL, ⁴Medical College of Wisconsin, Milwaukee, WI
*Purpose: Thymoglobulin® (r-ATG) has been used as induction therapy in liver transplantation (LT). No prospective, randomized, controlled, trial (RCT) has been performed to evaluate effect…

« Previous Page
1
…
3
4
5
6
7
…
27
Next Page »